To reach the next value inflection
LicenseRx asset brief
Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases
Probability of Success
23% · grade C · Medium data confidence
Model PoS 23% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.
Data maturity (22%)
59
Preclinical; human data.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
77
Oncology, Inflammation -- active buyer appetite.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
62
Public evidence mentions: human, mouse.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →